摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-benzyl-8-carbamoyl-[3H]-imidazo[5,1-d]-1,2,3,5-tetrazin-4-one | 85623-02-5

中文名称
——
中文别名
——
英文名称
3-benzyl-8-carbamoyl-[3H]-imidazo[5,1-d]-1,2,3,5-tetrazin-4-one
英文别名
3-Benzyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide;3-benzyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
3-benzyl-8-carbamoyl-[3H]-imidazo[5,1-d]-1,2,3,5-tetrazin-4-one化学式
CAS
85623-02-5
化学式
C12H10N6O2
mdl
——
分子量
270.25
InChiKey
LNPSWLFCAODLDZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    600.7±57.0 °C(Predicted)
  • 密度:
    1.61±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    106
  • 氢给体数:
    1
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2933990090

SDS

SDS:5ad8103204fc4843032f8587327c7cf9
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-benzyl-8-carbamoyl-[3H]-imidazo[5,1-d]-1,2,3,5-tetrazin-4-one 在 sodium tetrahydroborate 作用下, 以 乙醇 为溶剂, 生成 4-氨基-5-咪唑甲酰胺
    参考文献:
    名称:
    Synthetic studies of 8-carbamoylimidazo-[5,1-d]-1,2,3,5-tetrazin-4(3H)-one: A key derivative of antitumour drug temozolomide
    摘要:
    DOI:
    10.1016/0960-894x(95)00586-i
  • 作为产物:
    参考文献:
    名称:
    A new route to the antitumour drug temozolomide, but not thiotemozolomide
    摘要:
    5-氨基咪唑-4-羧酸与烷基异氰酸酯的相互作用产生N-取代的1-氨基甲酰基咪唑,这些化合物可经硝化反应环化为咪唑并[5,1-d][1,2,3,5]四嗪-4(3H)-酮,包括替莫唑胺3a;与此类似,与甲基异硫氰酸酯反应后,再经硝化反应,可得到新型环系咪唑并[1,5-b][1,2,4]噻二唑的硝基甲氨基衍生物11。
    DOI:
    10.1039/a606159a
点击查看最新优质反应信息

文献信息

  • A new route to the antitumour drug temozolomide, but not thiotemozolomide
    作者:Yongfeng Wang、Philip R. Lowe、William T. Thomson、Jonathan Clark、Malcolm F. G. Stevens
    DOI:10.1039/a606159a
    日期:——
    Interaction of 5-aminoimidazole-4-carboxamide with alkyl isocyanates yields N-substituted 1-carbamoylimidazoles which can be cyclised to imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-ones, including temozolomide 3a, on nitrosation; a similar reaction with methyl isothiocyanate, followed by nitrosation, affords the nitrosomethylamino derivative 11 of a new ring-system, imidazo[1,5-b][1,2,4]thiadiazole.
    5-氨基咪唑-4-羧酸与烷基异氰酸酯的相互作用产生N-取代的1-氨基甲酰基咪唑,这些化合物可经硝化反应环化为咪唑并[5,1-d][1,2,3,5]四嗪-4(3H)-酮,包括替莫唑胺3a;与此类似,与甲基异硫氰酸酯反应后,再经硝化反应,可得到新型环系咪唑并[1,5-b][1,2,4]噻二唑的硝基甲氨基衍生物11。
  • [EN] METHODS AND INTERMEDIATES FOR THE SYNTHESIS OF 4-OXO-3,4-DIHYDRO-IMIDAZO[5,1-D][1,2,3,5]TETRAZINES<br/>[FR] PROCÉDÉS ET INTERMÉDIAIRES POUR EFFECTUER LA SYNTHÈSE DE 4-OXO-3,4-DIHYDRO-IMIDAZO[5,1-D][1,2,3,5]TÉTRAZINES
    申请人:PHARMINOX LTD
    公开号:WO2011107726A1
    公开(公告)日:2011-09-09
    The present invention provides a compound of general formula (II), or a salt or solvate thereof wherein A is independently -A1, -A2, -A3, -A4, -A5, -A6, or -A7, wherein: -A1 is independently C5-12heteroaryl, and is optionally substituted; -A2 is independently thioamido or substituted thioamido; -A3 is independently imidamido, substituted imidamido, N-hydroxyimidamido, or substituted N-hydroxyimidamido; -A4 is independently hydroxamic acid or hydroxamate; -A5 is independently carboxamide or substituted carboxamide; -A6 is independently aliphatic C2-6alkenyl, and is optionally substituted; and -A7 is independently carboxy or C1-4alkyl-carboxylate; and its use in the synthesis of temozolomide and analogues thereof.
    本发明提供了通式(II)的化合物,或其盐或溶剂化合物,其中A独立地为-A1、-A2、-A3、-A4、-A5、-A6或-A7,其中:-A1独立地为C5-12杂环芳基,并且可以被取代;-A2独立地为硫代酰胺或取代硫代酰胺;-A3独立地为咪唑酰胺、取代咪唑酰胺、N-羟基咪唑酰胺或取代N-羟基咪唑酰胺;-A4独立地为羟肟酸或羟肟酸酯;-A5独立地为羧酰胺或取代羧酰胺;-A6独立地为脂肪族C2-6烯基,并且可以被取代;-A7独立地为羧基或C1-4烷基羧酸酯;以及其在替莫唑胺及其类似物的合成中的用途。
  • Synthesis and growth-inhibitory activities of imidazo[5,1-<i>d</i>]-1,2,3,5-tetrazine-8-carboxamides related to the anti-tumour drug temozolomide, with appended silicon, benzyl and heteromethyl groups at the 3-position
    作者:David Cousin、Marc G. Hummersone、Tracey D. Bradshaw、Jihong Zhang、Christopher J. Moody、Magdalena B. Foreiter、Helen S. Summers、William Lewis、Richard T. Wheelhouse、Malcolm F. G. Stevens
    DOI:10.1039/c7md00554g
    日期:——

    The synthesis and biological evaluation of imidazotetrazines substituted at N-3 is described.

    对N-3位取代的咪唑四氮唑类化合物的合成和生物评价进行了描述。
  • Methods and Intermediates for the Synthesis of 4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazines
    申请人:Hummersone Marc Geoffery
    公开号:US20130012706A1
    公开(公告)日:2013-01-10
    The present invention provides a compound of general formula (II), or a salt or solvate thereof: wherein A is independently -A 1 , -A 2 , -A 3 , -A 4 , -A 5 , -A 6 , or -A 7 , wherein: -A 1 is independently C 5-12 heteroaryl, and is optionally substituted; -A 2 is independently thioamido or substituted thioamido; -A 3 is independently imidamido, substituted imidamido, N-hydroxyimidamido, or substituted N-hydroxyimidamido; -A 4 is independently hydroxamic acid or hydroxamate; -A 5 is independently carboxamide or substituted carboxamide; -A 6 is independently aliphatic C 2-6 alkenyl, and is optionally substituted; and -A 7 is independently carboxy or C 1-4 alkyl-carboxylate; and its use in the synthesis of temozolomide and analogues thereof.
    本发明提供一种通式(II)的化合物或其盐或溶剂化物:其中A独立地为-A1,-A2,-A3,-A4,-A5,-A6或-A7,其中:-A1独立地为C5-12杂环芳基,并且可以被取代;-A2独立地为硫酰胺基或取代硫酰胺基;-A3独立地为咪唑酰胺基,取代咪唑酰胺基,N-羟基咪唑酰胺基或取代N-羟基咪唑酰胺基;-A4独立地为羟肟酸或羟肟酸盐;-A5独立地为羧酰胺或取代羧酰胺;-A6独立地为脂肪族C2-6烯基,并且可以被取代;-A7独立地为羧基或C1-4烷基羧酸盐;以及其在替莫唑胺及其类似物的合成中的用途。
  • 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use
    申请人:Stevens Malcolm Francis Graham
    公开号:US20100286088A1
    公开(公告)日:2010-11-11
    The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (collectively referred to herein as 3TM compounds). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.
    本发明涉及治疗化合物领域,更具体地涉及某些3-取代-4-氧代-3,4-二氢咪唑[5,1-d][1,2,3,5]四嗪-8-羧酸酰胺(统称为3TM化合物)。本发明还涉及包含这种化合物的制药组合物,以及在体内外使用这种化合物和组合物来抑制细胞增殖,在治疗增生性疾病如癌症等方面的应用,以及制备这种化合物的方法。
查看更多

同类化合物

米托唑胺 氰基替莫唑胺 替莫唑胺 N-[4-(2-氟苯甲酰)-1,3-二甲基-1H-吡唑-5-基]-N-甲基苯酰胺 3-(2H3)甲基-4-氧代-3,4-二氢咪唑并[5,1-d][1,2,3,5]四嗪-8-甲酰胺 3-(2-氯乙基)-N-甲基-4-氧代-3,4-二氢咪唑并[5,1-d][1,2,3,5]四嗪-8-甲酰胺 3-(2-氯乙基)-N,N-二甲基-4-氧代-3,4-二氢咪唑并[5,1-d][1,2,3,5]四嗪-8-甲酰胺 3-(2-氯乙基)-4-氧代-3H-咪唑并(5,1-d)-1,2,3,5-四嗪-8-羧酸 3,4-二氢-3-甲基-4-氧代咪唑并[5,1-D]-1,2,3,5-四嗪-8-甲酰胺酸 3-cyclohexyl-8-(pyrrolidinocarbonyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-cyclohexyl-8-(piperidinocarbonyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-cyclohexyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazin-8-N-methylcarboxamide ethyl 3-cyclohexyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate 3-cyclohexyl-8-(morpholinocarbonyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one S-n-butyl 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carbothioate 3-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(isopropylthio)-7-phenylimidazo[1,2-b][1,2,4,5]tetrazine 8-(morpholinocarbonyl)-3-(p-tolyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 4-oxo-3-(p-tolyl)imidazo[5,1-d][1,2,3,5]tetrazin-8-N-methylcarboxamide ethyl 4-oxo-3-(p-tolyl)imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate 8-(piperidinocarbonyl)-3-(p-tolyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3,8-dimethylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 8-acetyl-3-methylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-(4-methylimidazol-1-yl)imidazo[1,2-b][1,2,4,5]tetrazin 3-methyl-4-oxo-N-(sulfamoyloxy)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 3-methyl-4-oxo-N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide N,N,3-trimethyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide methyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carbimidothioate hydroiodide N,3-dimethyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide n-octyl 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylate 3-[2-(2-{2-[2-(dimethylamino)ethylcarbamoyl]-1-methylimidazol-4-ylcarbamoyl}-1-methylimidazol-4-ylcarbamoyl)-1-methylimidazol-4-yl]-3,4-dihydro-3-methyl-4-oxoimdazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 3-(5-{5-[2-(dimethylamino)ethylcarbamoyl]-1-methyl-pyrrol-3-ylcarbamoyl}-1-methylpyrrol-3-yl)-3,4-dihydro-3-methyl-4-oxoimdazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide hexyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate n-butyl 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylate 3-(2-{2-[2-(dimethylamino)ethylcarbamoyl]-1-methylimidazol-4-ylcarbamoyl}-1-methylimidazol-4-yl)-3,4-dihydro-3-methyl-4-oxoimdazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 3-{2-[2-(dimethylamino)ethylcarbamoyl]-1-methylimidazol-4-yl}-3,4-dihydro-3-methyl-4-oxoimdazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 8-carbamoyl-3-(2-trimethylsilylethoxy)methylimidazo<5,1-d>-1,2,3,5-tetrazin-4(3H)-one nor-temozolomide ethyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate 8-carbamoyl-3-trimethylsilylmethylimidazo<5,1-d>-1,2,3,5-tetrazin-4(3H)-one Temozolomide hydrochloride methyl 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylate [3-N-11C,13C-methyl]temozolomide [4-11C-carbonyl]temozolomide [3-N-11C-methyl]temozolomide N-(2,2-dimethoxyethyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboximidamide hydroiodide 3-(p-chlorophenyl)-8-(piperidinocarbonyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 8-(morpholinocarbonyl)-3-phenylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(propylthio)imidazo[1,2-b][1,2,4,5]tetrazine Imidazo[5,1-d][1,2,3,5]tetrazine 3-(2-(N-(4-fluorophenyl)-N-methylamino)ethyl)-4-oxo-3H,4H-imidazo[1,5-d][1,2,3,5]tetrazine-8-carboxamide